SENORES

Senores Pharmaceuticals Balance Sheet

₹1,390.00+0.10%
Market cap
₹6,401 crore
P/E
50.7
P/B
3.20
ROE
16.4%
Dividend yield
1.20%

As of Mar 2022, Senores Pharmaceuticals had total assets of ₹13,700 crore and borrowings of ₹1,200 crore, against shareholders' equity of ₹9,000 crore — a debt-to-equity ratio of 0.13. Borrowings rose 1,817.24% from Mar 2023.

Senores Pharmaceuticals balance sheet

As at each financial year end, newest first. H1 = half-year.

Senores Pharmaceuticals balance sheet (₹ crore)
ItemMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital5009.8130.5146.0546.05
Reserves8,50010.1141.5889.91189
Borrowings1,20062.59258315342
Other liabilities3,50022.9613399.86297
Total liabilities13,7001316221,2271,604
Fixed assets6,50016.2182260366
Capital work in progress400100100100100
Investments2,50026.21124245321
Other assets4,30039.32187368481
Total assets13,7001316221,2271,604

Balance sheet ratios

Debt to equity
0.13

Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Senores Pharmaceuticals balance sheet — frequently asked questions

What is the total debt of Senores Pharmaceuticals?

Senores Pharmaceuticals reported borrowings of ₹1,200 crore as of Mar 2022, compared with ₹62.59 crore as of Mar 2023.

What is Senores Pharmaceuticals' debt-to-equity ratio?

Based on the Mar 2022 balance sheet, Senores Pharmaceuticals' debt-to-equity ratio is 0.13 — borrowings of ₹1,200 crore against equity capital and reserves of ₹9,000 crore.

What are Senores Pharmaceuticals' total assets?

Senores Pharmaceuticals' total assets were ₹13,700 crore as of Mar 2022, including fixed assets of ₹6,500 crore and investments of ₹2,500 crore.

Same Data For Peers

Trade Senores Pharmaceuticals With ATS

Track SENORES live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.